NEXVET ANNOUNCES US$31.5 MILLION FINANCING
NEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]